期刊
NEUROGASTROENTEROLOGY AND MOTILITY
卷 23, 期 7, 页码 606-E249出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2982.2011.01714.x
关键词
esophageal motility; mosapride; secondary peristalsis
资金
- National Science Council, Taiwan [NSC 97-2314-B-303-014-MY2]
Background Secondary peristalsis is important for the clearance of refluxate or retained food bolus from the esophagus. Mosapride is a prokinetic agent that enhances GI motility by stimulating 5-hydroxytrypatamine(4) (5-HT4) receptors, but its effects on secondary peristalsis are yet unclear in humans. We aimed to investigate the effect of a 5-HT4 agonist mosapride on esophageal distension-induced secondary peristalsis in normal subjects. Methods After a baseline recording esophageal motility, secondary peristalsis was generated by slow and rapid mid-esophageal injections of air in 15 healthy subjects. Two separate sessions with 40 mg oral mosapride or placebo were randomly performed to test their effects on esophageal secondary peristalsis. Key Results Mosapride decreased the threshold volume for triggering secondary peristalsis during rapid air distension (4.5 +/- 0.3 vs 5.3 +/- 0.4 mL; P = 0.04) but not slow air distension (14.3 +/- 1.2 vs 13.3 +/- 1.3 mL; P = 0.41). Secondary peristalsis was triggered more frequently in response to rapid air distension after application of mosapride [100% (90-100%) vs 90% (80-100%); P = 0.02]. Mosapride significantly increased pressure wave amplitudes of secondary peristalsis during slow (135.4 +/- 13.8 vs 105.0 +/- 12.9 mmHg; P = 0.001) and rapid air distensions (124.0 +/- 11.6 vs 95.9 +/- 14.0 mmHg; P = 0.002). Conclusions & Inferences Mosapride enhances sensitivity to distension-induced secondary peristalsis and facilitates secondary peristaltic contractility. These data provide an evidence for modulation of esophageal secondary peristalsis by the 5-HT4 agonist mosapride, as well support for its clinical utility.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据